mulnitorsen (Andes-1537)
/ Andes Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 9
Of
9
Go to page
1
February 24, 2022
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
(clinicaltrials.gov)
- P1 | N=67 | Completed | Sponsor: Andes Biotechnologies | Active, not recruiting ➔ Completed
Trial completion • Cervical Cancer • Colorectal Cancer • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • HER-2 • KRAS • NRAS
December 10, 2021
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
(clinicaltrials.gov)
- P1; N=67; Active, not recruiting; Sponsor: Andes Biotechnologies; Recruiting ➔ Active, not recruiting; N=139 ➔ 67; Trial completion date: Nov 2022 ➔ Apr 2022
Clinical • Enrollment change • Enrollment closed • Trial completion date • Cervical Cancer • Colorectal Cancer • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • HER-2 • KRAS • MRI • NRAS
November 09, 2021
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
(clinicaltrials.gov)
- P1; N=139; Recruiting; Sponsor: Andes Biotechnologies; Trial completion date: Sep 2021 ➔ Nov 2022; Trial primary completion date: Sep 2021 ➔ Apr 2022
Clinical • Trial completion date • Trial primary completion date • Cervical Cancer • Colorectal Cancer • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • HER-2 • KRAS • MRI • NRAS
March 10, 2021
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
(clinicaltrials.gov)
- P1; N=124; Recruiting; Sponsor: Andes Biotechnologies; Trial completion date: Apr 2021 ➔ Sep 2021; Trial primary completion date: Apr 2021 ➔ Sep 2021
Clinical • Trial completion date • Trial primary completion date • Cervical Cancer • Cholangiocarcinoma • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • HER-2
May 13, 2020
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
(clinicaltrials.gov)
- P1; N=144; Recruiting; Sponsor: Andes Biotechnologies; Active, not recruiting ➔ Recruiting
Clinical • Enrollment open • Biliary Cancer • Cervical Cancer • Cholangiocarcinoma • Colorectal Cancer • Gall Bladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • KRAS • NRAS
March 26, 2020
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
(clinicaltrials.gov)
- P1; N=144; Active, not recruiting; Sponsor: Andes Biotechnologies; Recruiting ➔ Active, not recruiting
Enrollment closed
March 21, 2020
Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors.
(PubMed, J Cancer)
- "Similarly, treatment of a high-grade bladder cancer PDX with Andes-1537S resulted in a strong inhibition of tumor growth. Our results suggest that ASncmtRNAs could be potent targets for bladder cancer as adjuvant therapy."
Journal • BCL2L1 • BIRC5 • CASP3
June 13, 2019
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
(clinicaltrials.gov)
- P1; N=144; Recruiting; Sponsor: Andes Biotechnologies
Clinical • New P1 trial
May 10, 2019
The Antisense long non-coding mitochondrial RNA(AS-ncmtRNA) interference with Andes-1537 as a novel treatment for Renal carcinoma
(AUA 2019)
- "These results support the potential use of Andes-1537 as a novel therapy for RCC."
1 to 9
Of
9
Go to page
1